Article

Epithelial delay, pain are concerns with new NSAID

Fort Lauderdale, FL-Administration of nepafenac ophthalmic suspension 0.1% (Nevanac, Alcon Laboratories) for epithelial healing and pain control resulted in delayed healing in patients who had undergone surface ablation, according to a report by Marguerite B. McDonald, MD, FACS, and William Trattler, MD, that was presented at the annual meeting of the Association for Research and Vision in Ophthalmology.

Related Videos
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Image credit: Ophthalmology Times; Dean McGee Eye Institute resident Ashley Ooms, MD, explores gray area strabismus surgery complications in AUPO poster
© 2025 MJH Life Sciences

All rights reserved.